(LEAD) Celltrion Q2 net profit jumps nearly sixfold on strong biosimilar sales
Facebook X More Pinterest Linked in Tumblr Reddit Facebook Messenger Copy URL URL is copied. Net profit for the three months that ended in June soared to 371.3 billion won (US$254.8 million) from 63.3 billion won in the same period last year, the company said in a press release. The company attributed the strong performance to increased sales of newer biosimilars, including Remsima SC, Steqeyma, Yuflyma and Vegzelma.
- ▪Facebook X More Pinterest Linked in Tumblr Reddit Facebook Messenger Copy URL URL is copied.
- ▪Net profit for the three months that ended in June soared to 371.3 billion won (US$254.8 million) from 63.3 billion won in the same period last year, the company said in a press release.
- ▪The company attributed the strong performance to increased sales of newer biosimilars, including Remsima SC, Steqeyma, Yuflyma and Vegzelma.
Yonhap publishes from South Korea and files mainly under world. We currently carry 326 of its stories.
Opening excerpt (first ~120 words) tap to expand
Facebook X More Pinterest Linked in Tumblr Reddit Facebook Messenger Copy URL URL is copied. OK (LEAD) Celltrion Q2 net profit jumps nearly sixfold on strong biosimilar sales Choi Kyong-ae All News 09:48 July 27, 2026 This will let Google show Yonhap news articles that match or are related to your search Add Yonhap as a preferred source on Google SHARE Facebook X Pinterest Linked in Tumblr Reddit Facebook Messenger Copy URL URL is copied. LIKE SAVE PRINT FONT SIZE ABCDEFG ABCDEFG ABCDEFG ABCDEFG ABCDEFG (ATTN: RECASTS throughout; ADDS photo) SEOUL, July 27 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical company, said Monday its second-quarter net profit jumped nearly sixfold from a year earlier, driven by strong sales of its expanding biosimilar portfolio.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Yonhap News Agency.
Discussion
0 commentsMore from Yonhap News Agency
